Oh-bbn Carcinogen
Oh-bbn Carcinogen - Related Videos
01:25
Mutagenicity and Carcinogenicity
0 Views •
2023
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
05:19
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
0 Views •
Cited by 5 •
2019
Murine bladder tumors are induced with the N-butyl-N-(4-hydroxybutyl) nitrosamine carcinogen (BBN). Bladder tumor generation is heterogeneous; therefore, an accurate assessment of tumor burden is needed before randomization to experimental treatment. Here we present a fast, reliable MRI protocol to assess tumor size and stage.
09:33
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
0 Views •
Cited by 3 •
2018
Evaluating the potency of environmental chemicals and drugs, to be enzymatically bioactivated to intermediates generating covalent DNA adducts, is an important field in the development of cancer and its treatment. Methods are described for compound activation to form DNA adducts, as well as techniques for their detection and quantification.
07:12
Neutrophil Isolation Protocol
0 Views •
Cited by 173 •
2008
Neutrophils are among the first cells to arrive on the site of inflammatory immune response, and their functions and mechanisms have been studied extensively in vitro. We demonstrate a standard density gradient separation method to isolate human neutrophils from whole blood using commercially available separation media.
06:02
A Computational Pipeline for Intergenic/Intragenic Enhancer RNA Quantification in Mouse Embryonic Stem Cells
0 Views •
2025
This protocol provides a streamlined computational pipeline for quantifying nascent enhancer transcripts. By integrating chromatin accessibility, chromatin feature, and transcriptional data, it enables accurate detection and strand-specific analysis of enhancer activity in complex intragenic regions, while remaining accessible to researchers without extensive bioinformatics training.
FAQs
Following administration, OH-BBN carcinogen is metabolized in the liver and bladder into reactive intermediates. These products can damage urothelial cells and cause DNA injury, creating molecular changes that support the later development of chemically induced lesions. The model therefore connects metabolic activation with tissue damage and subsequent bladder tumor formation.
Metabolism in the liver and bladder places the compound within a process that generates reactive intermediates in more than one anatomical site. In the bladder, these intermediates can affect urothelial cells directly and contribute to DNA damage. This metabolic context helps researchers investigate how chemical exposure progresses toward bladder carcinogenesis.
The model supports longitudinal investigation of urothelial lesions, tumor progression, and biomarker changes. Examining these outcomes over time allows researchers to relate early chemical injury to later disease development rather than considering tumor presence as an isolated endpoint. Such comparisons can clarify disease evolution and help identify measurable indicators of treatment or prevention effects.
Researchers can apply preventive or therapeutic interventions within the chemically induced bladder cancer model and then assess their effects on lesions, tumor progression, biomarkers, or other disease-related outcomes. This design helps determine whether an intervention influences carcinogenesis or established tumor behavior, providing experimental evidence before a potential clinical study.
A study may examine the full pattern of chemically induced urothelial disease, including lesion development, progression, biomarker changes, and responses to an intervention. Considering several outcomes provides a broader assessment than measuring tumor occurrence alone. It can also help connect cellular injury with pathological and molecular changes relevant to bladder cancer research.
The model gives medical researchers a controlled way to investigate mechanisms of bladder carcinogenesis and to test candidate preventive or therapeutic approaches. Its value lies in linking chemical exposure with urothelial lesions, tumor progression, and biomarker responses. Findings can guide the selection and evaluation of interventions before they advance to clinical studies.